Platelet aggregation pathway receptors

Platelet aggregation pathway receptors are a diverse group of cell-surface proteins on platelets that coordinate the complex physiological process of blood clotting and the pathological process of thrombosis [1]. This collective target includes G protein-coupled receptors (GPCRs) such as the P2Y12 and P2Y1 purinergic receptors, which respond to adenosine diphosphate (ADP), and Protease-activated receptors (PAR-1 and PAR-4), which are activated by thrombin [2, 3]. Additionally, the group includes the integrin alpha-IIb/beta-3 (Glycoprotein IIb/IIIa), which serves as the final common pathway for aggregation by binding fibrinogen to cross-link adjacent platelets [4]. Upon vascular injury, these receptors initiate intracellular signaling cascades that lead to platelet shape change, degranulation, and the formation of a stable hemostatic plug [5]. Overactivation of these pathways is a primary driver of arterial thrombosis, leading to life-threatening conditions such as myocardial infarction and ischemic stroke [6]. Pharmacological agents targeting these receptors, such as P2Y12 inhibitors (e.g., clopidogrel) and GPIIb/IIIa antagonists (e.g., tirofiban), are essential in modern cardiology to prevent thrombotic events [1, 7]. The major therapeutic challenge associated with these targets is maintaining a balance between preventing pathological thrombosis and preserving normal hemostasis to avoid severe bleeding complications [8]. (Sources: [1] StatPearls: Antiplatelet Agents; [2] UniProt: P2Y purinoceptor 12; [3] PubMed: PAR-1 antagonists; [4] NCBI: Integrin alpha-IIb; [5] PubMed: Platelet activation and aggregation; [6] NIH: Cardiovascular Disease and Platelets; [7] PubMed: P2Y12 inhibitors in ACS; [8] Journal of Thrombosis and Haemostasis: Bleeding risk assessment).

Other names

Platelet surface receptorsAntiplatelet targetsThrombocyte aggregation receptorsHemostatic receptors

Inhibition of ADP binding to P2Y12 receptors, competitive or non-competitive blockade of fibrinogen binding to the Glycoprotein IIb/IIIa (Integrin alpha-IIb/beta-3) complex, antagonism of thrombin-induced activation via Protease-activated receptor 1 (PAR-1), and inhibition of Thromboxane A2 receptor (TP) signaling.